Evidence map›Paper›PMID 35106480›Full record

ArticleJournal of biotechnology and biomedicine2022

AI-Driven Image Analysis in Central Nervous System Tumors-Traditional Machine Learning, Deep Learning and Hybrid Models.

A V Krauze, Y Zhuge, R Zhao, E Tasci, K Camphausen

Abstract read
In one paragraph

Article in Journal of biotechnology and biomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A V KrauzeCenter for Cancer Research, National Cancer Institute, NIH, Building 10, Room B2-3637, Bethesda, USA.
Y ZhugeCenter for Cancer Research, National Cancer Institute, NIH, Building 10, Room B2-3637, Bethesda, USA.
R ZhaoUniversity of British Columbia, Faculty of Medicine, 317 - 2194 Health Sciences Mall, Vancouver, Canada.
E TasciCenter for Cancer Research, National Cancer Institute, NIH, Building 10, Room B2-3637, Bethesda, USA.
K CamphausenCenter for Cancer Research, National Cancer Institute, NIH, Building 10, Room B2-3637, Bethesda, USA.

Funding

Radiation Oncology Branch - Radiation ClinicZIDBC010990 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$136.0M
Pre-clinical Development of Radiation Sensitizers for Patients with GlioblastomaZIASC010372 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$12.0M
Radiation Oncology Branch - Radiation ClinicZ01BC010990 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2008 to 2008
$4.8M
Advancing clinically meaningful AI algorithms to improve oncologic outcomesZIABC012096 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAUZE, ANDRA · 2022 to 2025
$847k
Prognostic and predictive clinical and proteomic biomarker discovery in GBMZIABC012094 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAUZE, ANDRA · 2022 to 2025
$847k
Using artificial intelligence and MRI to address limitations in glioblastomaZIABC012092 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAUZE, ANDRA · 2022 to 2025
$847k
Proteogenomic characterization and biomarker discovery in glioblastomaZIABC012093 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAUZE, ANDRA · 2022 to 2025
$847k
Intramural NIH HHS Z01 BC010990Intramural NIH HHS ZID BC010990
6 · The paper itself

Abstract

The interpretation of imaging in medicine in general and in oncology specifically remains problematic due to several limitations which include the need to incorporate detailed clinical history, patient and disease-specific history, clinical exam features, previous and ongoing treatment, and account for the dependency on reproducible human interpretation of multiple factors with incomplete data linkage. To standardize reporting, minimize bias, expedite management, and improve outcomes, the use of Artificial Intelligence (AI) has gained significant prominence in imaging analysis. In oncology, AI methods have as a result been explored in most cancer types with ongoing progress in employing AI towards imaging for oncology treatment, assessing treatment response, and understanding and communicating prognosis. Challenges remain with limited available data sets, variability in imaging changes over time augmented by a growing heterogeneity in analysis approaches. We review the imaging analysis workflow and examine how hand-crafted features also referred to as traditional Machine Learning (ML), Deep Learning (DL) approaches, and hybrid analyses, are being employed in AI-driven imaging analysis in central nervous system tumors. ML, DL, and hybrid approaches coexist, and their combination may produce superior results although data in this space is as yet novel, and conclusions and pitfalls have yet to be fully explored. We note the growing technical complexities that may become increasingly separated from the clinic and enforce the acute need for clinician engagement to guide progress and ensure that conclusions derived from AI-driven imaging analysis reflect that same level of scrutiny lent to other avenues of clinical research.

Identifiers

PMID35106480
PMCPMC8802234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.